98%
921
2 minutes
20
This study sought to characterize images of cancer patients generated by Artificial Intelligence (AI) text-to-image tools, and assess whether images differed by cancer type or AI tool, to elucidate the potential implications of using AI-generated images in health communication. Two generative AI-based tools, and , were prompted to produce images of a "cancer patient," "breast cancer patient," "lung cancer patient," and "prostate cancer patient". Images ( = 320) were coded for perceived demographics, illness features, affect, cancer symbols, setting, and photorealism. Analysis revealed that AI tools commonly depicted cancer patients as White (83.2%) and middle-aged or older (87.5%). Compared to general cancer patient images, breast cancer patients were portrayed as younger, while prostate and lung cancer patients were depicted as older. Breast cancer patients were also more frequently depicted as healthy and displaying positive affect, while lung cancer patients were more often depicted as ill and showing negative affect. Differences were also found between the AI tools, with images featuring more racial diversity and being less photorealistic compared to images produced by . Because generative AI tools may produce images of cancer patients that are limited on some dimensions of diversity, and in some cases may reinforce stereotypes (eg, breast cancer patients as healthy and happy, lung cancer patients as ill and hopeless), it is critical to consider biases that may exist in these models - and the potential societal implications of using AI-generated images of cancer patients - before these tools are deployed in cancer communication efforts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10410236.2025.2537807 | DOI Listing |
Nutr Clin Pract
September 2025
Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Objective: The cachexia index (CXI) demonstrates potential as both a diagnostic tool for cachexia and a prognostic tool for survival in cancer. However, CXI's predictive value has not been verified in cervical cancer. The purpose of this study is to investigate the prognostic value of the CXI in patients with cervical cancer treated with radiotherapy.
View Article and Find Full Text PDFBMC Cancer
September 2025
Department of Gastrointestinal Surgery, Affiliated Hospital of Chengde Medical University, No. 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.
View Article and Find Full Text PDFBreast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.